Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.

about

Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.

Item

http://www.wikidata.org/entity/Q38880396

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Long-term efficacy and tolerab ...... fuse scleroderma skin disease.

@en

type

Item

label

Long-term efficacy and tolerab ...... fuse scleroderma skin disease.

@en

prefLabel

Long-term efficacy and tolerab ...... fuse scleroderma skin disease.

@en

P1476

Long-term efficacy and tolerab ...... ffuse scleroderma skin disease

@en

P2093

Anton Rajadurai

http://www.w3.org/2001/XMLSchema#string

Catherine Hill

http://www.w3.org/2001/XMLSchema#string

Daniel Boulos

http://www.w3.org/2001/XMLSchema#string

Gene-Siew Ngian

http://www.w3.org/2001/XMLSchema#string

Janet Roddy

http://www.w3.org/2001/XMLSchema#string

Joanne Sahhar

http://www.w3.org/2001/XMLSchema#string

Kathleen Elford

http://www.w3.org/2001/XMLSchema#string

Mandana Nikpour

http://www.w3.org/2001/XMLSchema#string

Peter Youssef

http://www.w3.org/2001/XMLSchema#string

Susanna Proudman

http://www.w3.org/2001/XMLSchema#string

P2860

Cellular and molecular mechanisms of fibrosis

The use of mycophenolate mofetil in transplant recipients.

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative.

The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase.

Cyclophosphamide versus placebo in scleroderma lung disease.

A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-ph

Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis

Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease.

Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.

Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis.

P304

481-488

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/1756-185X.13035

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

C E Owen

P577

2017-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28337853

http://www.w3.org/2001/XMLSchema#string